Frequently asked questions
What are the current treatment options for low-risk (early-stage) prostate cancer?
For the majority of patients diagnosed with localised low-risk prostate cancer, the current treatments are active surveillance, radical treatments (radical prostatectomy: total surgical ablation of the prostate, brachytherapy and external radiotherapy) or focal thermal (HIFU and cryotherapy) or non-thermal (vascular targeted photodynamic therapy) treatments.
Is treatment always necessary?
For patients with low-risk localised prostate cancer, i.e. a cancer presenting a low risk of progression and of propagation, treatment is not always necessary as progression of the disease is slow and regular visits to the doctor will evaluate that no progression has occurred. This approach complies with European and American guidelines and is called “Active Surveillance”.
Is there an alternative to radical treatments?
Over the last few years, an alternative to surgery or other radical treatments has been developed for patients with low-risk localised prostate cancer. It can be offered to patients under active surveillance who meet the criteria of the indication and who wish to be treated with a targeted method. This method aims at selectively destroying the low risk cancer tumour in the regions of the gland, previously identified as containing the cancer by means of biopsies. This new treatment option has been called focal therapy.